-
Comparative data shows Veyonda® significantly boosts the effectiveness of a promising new form of radiation therapy (177LuPSMA) in advanced prostate cancer
-
177LuPSMA therapy is the subject of a recent US$6 billion series of acquisitions
-
Veyonda® improves three key measures of response to 177LuPSMA therapy – falls in PSA levels (doubled), progression-free survival (quadrupled) and treatment duration rates (tripled)
-
Noxopharm foresees Veyonda® as standard companion drug for 177LuPSMA therapy
For further information please download the attached PDF:
Download this document
